{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:26:27Z","timestamp":1766579187617,"version":"3.41.0"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"61","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,28]]},"DOI":"10.18632\/oncotarget.21870","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T14:47:12Z","timestamp":1508251632000},"page":"103274-103282","source":"Crossref","is-referenced-by-count":15,"title":["Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression"],"prefix":"10.18632","volume":"8","author":[{"given":"Kseniya","family":"Petrova-Drus","sequence":"first","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Margolskee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Barouk-Fox","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"volume-title":"Chronic myelomonocytic leukaemia","year":"2008","author":"Thiele","key":"1"},{"key":"2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Sultan","year":"1982","journal-title":"Br J Haematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Brunning","year":"2002","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Vardiman","year":"2016","journal-title":"Blood"},{"key":"6","first-page":"52","article-title":"Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system","volume":"6","author":"Schneider","year":"1992","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","article-title":"Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival","volume":"68","author":"Hamblin","year":"1988","journal-title":"Br J Haematol"},{"key":"8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Aul","year":"1997","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Levis","year":"2012","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Nachtkamp","year":"2013","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Haferlach","year":"2010","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Maciejewski","year":"2015","journal-title":"Haematologica"},{"key":"13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Brisci","year":"2014","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Komrokji","year":"2013","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Haferlach","year":"2013","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Zibellini","year":"2016","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/modpathol.3800707","article-title":"Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology","volume":"19","author":"Vance","year":"2006","journal-title":"Mod Pathol"},{"key":"18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.1992.tb01587.x","article-title":"Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients","volume":"48","author":"Hufnagl","year":"1992","journal-title":"Eur J Haematol"},{"key":"19","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Orazi","year":"2005","journal-title":"Haematologica"},{"key":"20","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2007-09-112953","article-title":"Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis","volume":"111","author":"Deliliers","year":"2008","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Green","year":"2009","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1038\/bcj.2017.17","article-title":"Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations","volume":"7","author":"Tefferi","year":"2017","journal-title":"Blood Cancer J"},{"key":"23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Cazzola","year":"2009","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3324\/haematol.2010.039875","article-title":"Myelodysplastic syndromes with bone marrow fibrosis","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-013-1776-3","article-title":"The clinical importance of moderate\/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"key":"26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Wang","year":"2014","journal-title":"Mod Pathol"},{"key":"27","doi-asserted-by":"publisher","first-page":"30492","DOI":"10.18632\/oncotarget.9026","article-title":"Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis","volume":"7","author":"Zamora","year":"2016","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Orazi","year":"2013","journal-title":"Mod Pathol"},{"key":"29","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Onida","year":"2010","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML--dysplastic versus proliferative type","volume":"22","author":"Aul","year":"1998","journal-title":"Leukemia Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(00)00159-4","article-title":"Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?","volume":"25","author":"Straka","year":"2001","journal-title":"Leukemia Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection","volume":"120","author":"Ravid","year":"2012","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0145-2126(01)00014-5","article-title":"Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution","volume":"25","author":"Pfeilstocker","year":"2001","journal-title":"Leukemia Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0145-2126(02)00021-8","article-title":"Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center","volume":"26","author":"Massague","year":"2002","journal-title":"Leukemia Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0145-2126(03)00006-7","article-title":"Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome","volume":"27","author":"Li","year":"2003","journal-title":"Leukemia Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00000478-199101000-00011","article-title":"Plasmacytoid T-zone cell proliferation in a patient with chronic myelomonocytic leukemia. Histologic and immunohistologic characterization","volume":"15","author":"Demirjian","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1097-0142(19920315)69:6<1457::AID-CNCR2820690625>3.0.CO;2-F","article-title":"Plasmacytoid monocyte proliferation associated with myeloproliferative disorders","volume":"69","author":"Chan","year":"1992","journal-title":"Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00277-013-1945-4","article-title":"Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis","volume":"93","author":"Tuchler","year":"2014","journal-title":"Ann Hematol"},{"key":"39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/his.12871","article-title":"Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study","volume":"68","author":"Stein","year":"2016","journal-title":"Histopathology"},{"key":"40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in polycythemia vera: Clinical and molecular correlates","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"41","first-page":"33","article-title":"Quantitation of megakaryocytes in normal bone marrow","volume":"10","author":"Belliveau","year":"1988","journal-title":"Anal Quant Cytol Histol"},{"key":"42","first-page":"177","volume-title":"Non-neoplastic megakaryocytic lineage disorders. Non-neoplastic disorders of bone marrow","author":"Wilson","year":"2008"},{"key":"43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000111532","article-title":"Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals","volume":"118","author":"Coleman","year":"2007","journal-title":"Acta Haematologica"},{"volume-title":"An International System for Human Cytogenetic Nomenclature","year":"2009","author":"ISCN","key":"44"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:57:28Z","timestamp":1750949848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":44,"journal-issue":{"issue":"61","published-print":{"date-parts":[[2017,11,28]]}},"alternative-id":["21870","29262560"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21870","relation":{},"ISSN":["1949-2553"],"issn-type":[{"type":"electronic","value":"1949-2553"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}